Key Highlights

  • Creo Medical Group Plc (LSE:CREO) shares fell 12.42% on 30 September 2026.
  • Revenue for the six months to 30 June 2026 rose 45% to £3.2 million.
  • Underlying operating costs fell 15% to £7.9 million, and the underlying operating loss narrowed by more than a quarter to £4.9 million.
  • Full-year Revenue growth guidance of 50% to 60% was maintained, with trading weighted to the second half.

Why Creo Medical (LSE:CREO) Is in Focus

Creo Medical Group Plc (LSE:CREO), the developer of advanced energy devices for minimally invasive surgical endoscopy, published its interim results on 30 September 2026. Despite headline growth and cost savings, the shares fell 12.42% as investors focused on the shape of the year and the remaining losses.

Key Reasons Behind the 12.42% Share Price Fall

The first reason is second-half dependence. Creo said trading is expected to be weighted towards the second half of the year. To meet full-year guidance of 50% to 60% growth, the company needs a much larger second-half revenue performance than the £3.2 million achieved in the first half. Investors often price in some risk when a large part of annual targets depends on later months.

The second reason is continued losses. Although the underlying operating loss narrowed to £4.9 million, the company still burns cash, and investors remain watchful of funding needs for a Business at this stage.

The third reason is expectation management. The first-half revenue figure of £3.2 million and 45% growth had already been flagged in a trading update in July 2026, so the interim results contained limited fresh upside, giving room for profit-taking.

Revenue Growth Drivers

Growth was supported by wider adoption of key products, including Speedboat, SpydrBlade Flex and MicroBlate Fine. Speedboat devices are used for advanced endoscopic procedures to remove lesions with less invasive techniques. Creo also expanded into new international markets, with notable progress across Latin America.

Management cited a healthy order book and continued clinical validation of its products as factors supporting full-year expectations.

Cost Reduction Programme

Creo continues to streamline operations. The company is outsourcing Manufacturing at its Chepstow Facility as part of its cost-reduction programme. Management expects this change to reduce annual operating costs by around 15% compared with FY25 levels.

Earlier in 2026, Creo reported full-year 2025 revenue of £6 million, up 50%, and agreed to sell its remaining stake in Creo Medical Europe alongside a £5.5 million fundraise. These steps were designed to create a leaner business with a clearer route towards profitability.

What Investors Are Watching

The first watch point is second-half revenue delivery against the 50% to 60% growth target.

The second watch point is the transition of manufacturing to outsourced partners without disruption to supply.

The third watch point is cash runway and any future financing needs.

The fourth watch point is clinical adoption, including new hospital accounts and procedure volumes across Europe, the US and Latin America.

Medtech Market Backdrop

Minimally invasive endoscopy is a growing area of surgery, as hospitals seek procedures that reduce recovery times and costs. Smaller device makers can grow quickly once products gain clinical acceptance, but they must manage cash carefully during the adoption phase.

Outlook

Creo Medical (LSE:CREO) is showing progress on revenue and costs, but the market wants proof of second-half delivery and a clearer path to profitability. Fourth-quarter trading updates, order book conversion and cash position disclosures will be the next catalysts for the stock.